ArticleThe Lancet regional health. Europe2021
Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1).
Article in The Lancet regional health. Europe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 31 citations in OpenAlex.
- Waning Measles Immunity and Sustained Rubella Seroprotection Among Adults in Istanbul, Türkiye.Medicina (Kaunas, Lithuania) · 2026Article
- Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.Open forum infectious diseases · 2026Article
- Assessment of Measles Immunity in the Croatian Population: A Retrospective Seroprevalence Study, 2015-2025.Vaccines · 2026Article
- Measles - retrospective study of cases reported in a national notification system, Czech Republic, 2018-2024.BMC public health · 2026Article
- Cross-sectional seroprevalence study of measles antibodies among children to identify gaps in population immunity, Ireland, 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Evaluation of measles immunity in the central black sea region of Türkiye.BMC infectious diseases · 2026Article
- Measles Seroprevalence and Associated Factors among Adult Individuals in the City Center of Şanlıurfa Province.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Loss of measles, mumps, and rubella immunity in pediatric cancer survivors following chemotherapy.BMC research notes · 2025Article
- Low Measles Seropositivity in Vaccinated Children.JAMA network open · 2025Article
- The Unprotected: Measles Seroprevalence in Children During the First Two Years of Life.Viruses · 2025Article
- Seroprevalence of Measles-, Mumps-, and Rubella-Specific Antibodies in Future Healthcare Workers in Serbia: A Cross-Sectional Study.Vaccines · 2025Article
- Surge in Measles Cases in Italy from August 2023 to January 2025: Characteristics of Cases and Public Health Relevance.Vaccines · 2025Article
- Herd Immunity to the Measles, Mumps and Rubella Viruses Among the Belgradian Population in May, 2024.Vaccines · 2025Article
- Seroprevalence against measles, Austria, stratified by birth years 1922 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population.Vaccines · 2025Article
- Seroprevalence of Mumps among Patients Attending Selected Hospitals in Kenya.The East African health research journal · 2025Article
- Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity.Journal of medical virology · 2024Observational
- Intrathecal immune reactivity against Measles-, Rubella-, and Varicella Zoster viruses is associated with cerebrospinal fluid inflammation in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China.Vaccines · 2024Article
- Immunity Against Measles in Korean Autologous Hematopoietic Stem Cell Transplant Recipients.Journal of Korean medical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe WHO European Region targets the elimination of measles, rubella, and the congenital rubella syndrome and welcomes mumps elimination via the joint MMR vaccine. In a push towards this elimination goal, Germany introduced a recommendation on MMR vaccination for adults in 2010 to prevent increasing numbers of measles cases among adults and to strengthen herd immunity.
methodsThe prevalence of anti-measles, -mumps, and -rubella IgG antibodies was analysed in 7,115 participants between the ages of 18 and 79 years in the German Health Interview and Examination Survey. Risk factors of seronegativity of adults born 1970 or later were determined.
findingsThe seroprevalence of anti-measles IgG antibodies was more than 97% in adults born before 1965 and less than 90% in adults born afterwards. Prevalence and GMTs declined with later years of birth. Seronegativity was associated with two-sided migration background and region of residence in East Germany. For anti-mumps IgG antibodies, the seroprevalence was less than 90% in almost all age groups. Prevalence and GMTs declined with later years of birth. Seronegativity was not associated with any socio-demographic factor. Anti-rubella IgG seropositivity was found in more than 90% of adults born before 1985. GMTs declined in younger age groups. Seronegativity was associated with birth between 1980 and 1993 and male gender. High socio-economic status lowered the odds of being seronegative.
interpretationThese data reinforce the implementation of the vaccination recommendation for adults and provide the basis for further evaluation of this measure.
fundingThe Federal Ministry of Health, Germany.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.